FAP-targeted PET/NIR in Lung Malignant Tumors

Summary

Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.

Eligibility

Inclusion Criteria:

* Age between 18 and 70 years old;
* Have complete clinical and imaging data;
* Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
* Able to retain sufficient tumor tissue for testing and research;
* Sign informed consent.

Exclusion Criteria:

* Previously combined with other malignant tumors or received other anti-tumor treatments;
* Failure to collect sufficient tumor tissue for testing and research;
* The duration of neoadjuvant therapy is less than 3 cycles;
* The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;
* Lack of clinical and imaging data;
* There are situations where other researchers consider it inappropriate to participate in this study

Conditions5

Browse More Trials